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Abstract 
 
Introduction: To assess the outcomes from multidisciplinary board meetings (MDM) for 
patients with breast cancer liver metastases (BCLM) and identify prognostic factors for 
survival.  
  
Materials and Methods: A retrospective review of MDM records for patients referred with 
BCLM to a tertiary centre between 2005-2016. Patient demographics, clinicopathological 
factors and intervention type were analysed to find predictive factors for overall survival. 
 
Results:  61 patients with BCLM were referred to the MDM. Treatment pathways included 
surgical resection (n=23), radiofrequency ablation (RFA, n=11), or chemotherapy (n=27).  
 
Surgical resection patients had an improved median overall survival compared to 
chemotherapy (49 v 20mo; p<0.001). RFA showed comparable survival benefit (37 v 20mo; 
p=0.011). Resection and RFA showed no significant difference in survival over one another 
(49 v 37mo; p=0.854). Survival analysis identified that resection (p=0.002) and RFA 
(p=0.001) were associated with improved overall survival compared to chemotherapy. 
 
Multivariate analysis identified extrahepatic disease (HR=14.21; p=0.044) and R0 resection 
(HR=0.068; p=0.023) as prognostic factors. 
 
Conclusions:  Surgical resection of BCLM may improve the overall survival in selected 
patient groups. This study identifies a cohort of patients, without extrahepatic disease and 
responsive to chemotherapy, who may particularly benefit from surgery. 
 
Keywords: Liver; Hepatic; Metastases; Resection; RFA; Chemotherapy 
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1. Introduction 
Breast cancer is the most prevalent female cancer. The most recent epidemiological study 
conducted by the World Health Organisation on cancer identified that there were 1.67 million 
new diagnoses of breast cancer in 2012(1). The global incidence of breast cancer has risen 
substantially over the past 30 years and continues to rise due to increased pervasiveness of 
risk factors(1-3). The survival of patients with breast cancer has improved over a similar time 
period. This has been attributed to the development of better systemic therapies and earlier 
diagnosis(4-6). The prevalence of distant metastases in invasive breast cancer can range from 
29.0% to 53.2%(2). The 5-year overall survival (OS) for localised breast cancer is 98.6%, 
which is prolonged, compared to 24.3% with distant metastases(7).  
 
The liver is the 3rd most common site for breast metastases(8,9). Approximately 50% of 
patients with metastatic breast cancer will eventually develop breast cancer liver metastases 
(BCLM) (10). Patients with solitary BCLM have a median survival of approximately 25 
months with chemotherapy(11,12). The 2nd international consensus guidelines for advanced 
breast cancer (ABC2) outlined that systemic therapy, with chemotherapy and hormone 
therapy, is the current first line treatment modality in patients with BCLM(13). However, 
there is a lack of knowledge as to the best treatment modalities in BCLM due to a paucity of 
randomised data for the use of loco-regional treatments. It is therefore currently 
recommended that both surgery and radio-frequency ablation (RFA) of liver deposits are 
carried out in a highly selective patient cohort. The most recent systematic review of resection 
and ablation identified that these treatments may, however, have the potential to improve 
survival producing 5-year OS rates between 21-61% and 27-41% respectfully(14).  
 
Resection and ablation are both used with curative intent in the treatment of both colorectal 
liver metastases (CLM) and neuroendocrine liver metastases.  Guidelines for both diseases 
indicate that hepatic resection is best indicated when it is possible to obtain a clear-margin 
resection with acceptable residual functioning volume, and controllable extrahepatic 
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disease(15,16). These provide favourable OS at 5-years compared to medical 
treatment(17,18). In the most recent systematic review for BCLM, however, no prognostic 
factors for survival were identified(14). Consequently there is a paucity of guidelines 
available to advise treatment in this cohort. Howlander et al. produced the only identified 
published guidelines in 2011(19). In the absence of randomised data on treatment for BCLM, 
a report on outcomes and identification of prognostic factors for OS in patients with BCLM 
would be valuable. 
 
The primary aim of this study is to compare the survival outcomes for patients with BCLM 
discussed at multidisciplinary board meetings (MDMs). Additionally, this study hoped to 
identify prognostic factors for OS in patients with BCLM. 
 
2. Materials and Methods 
A retrospective review was conducted for patients referred for treatment of BCLM at King’s 
College Hospital, a tertiary centre for liver disease, between January 2005 and August 2016. 
The review utilised MDM and clinical records for all consecutive patients referred in this time 
period. Confirmation of BCLM was made via radiological criteria and clinical evaluation 
with/without percutaneous core liver biopsy. The study cohort included patients who 
underwent resection, radiofrequency ablation (RFA) or chemotherapy as their definitive 
treatment for BCLM. Patients with concurrent extrahepatic metastases were also included.  
 
Patient demographics, clinicopathological characteristics, intervention type and survival data 
were collected. The estrogen receptor (ER), progesterone receptor (PR) and HER2 status were 
assessed for both primary tumour and BCLM. Staging was based upon the most up-to-date 
guidelines from the American Joint Committee on Cancer(20). Synchronous presentation was 
defined as a time interval between the diagnosis of the primary breast cancer and 
development of BCLM within 6 months. The disease free interval was calculated as the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4 
difference in time between treatment for primary cancer and diagnosis of BCLM. Response to 
chemotherapy was calculated according to RECIST criteria(21). Disease free survival (DFS) 
and OS were calculated from the date of commencement of chemotherapy regimen or 
surgery, as applicable. DFS was calculated by presence of recurrence by the latest follow-up 
recorded.  
 
2.1 Treatment algorithm 
Case-by-case based discussion at the MDM was carried out to reach a consensus with regards 
to treatment modality. All patients were discussed in a MDM with surgeons and oncologists 
present. Prior to discussion at the MDM it was established whether patients demonstrated 
systemic dissemination via staging. If patients had systemic disease they were treated with 
first line chemotherapy and subsequently evaluated in the MDM to identify if systemic 
control had been obtained. A treatment algorithm, outlined in figure 1, was used to aid 
management decision. Patients with unresectable disease were offered chemotherapy. If these 
patients had a good or partial response they were restaged for discussion at a future MDM. 
Those who had resectable metastases underwent positron emission tomography-computed 
tomography (PET-CT) to determine the presence of extrahepatic disease. For those with 
isolated BCLM, they underwent hepatectomy or RFA. Those patients with BCLM and a 
single bony metastasis were treated using the same algorithm as those with isolated BCLM on 
a case-by-case consideration. Otherwise, those with extrahepatic disease had chemotherapy.  
 
Liver Resections were performed either via laparoscopic or open techniques. Major resections 
were defined as those consisting of 3 or more liver segments. Data regarding postoperative 
morbidity and mortality, R0 resection, and repeat liver resections were collected. 
Postoperative morbidity was defined as complications within 90 days of surgery according to 
the Clavien-Dindo classification(22). 
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2.2 Follow up 
Follow up schedule was dependent on MDM outcome. Those who underwent surgery were 
followed up within one month post-operatively following MDM discussion with regards to 
histopathological findings and the resection margins of the tumour. Those who had RFA had 
a follow up interval CT scan at 6 weeks post-RFA with MDM discussion of the scan the 
following week and clinic review at 8 weeks. Those who were referred to oncology for 
systemic chemotherapy were discussed in the MDM after completion of their intended 
treatment course and assessment of their response to treatment.  
 
2.3 Data Analysis:  
Continuous variables were analysed using one-way ANOVA and Kruskal-Wallis tests 
according to whether the data was parametric. The type of distribution was confirmed by a 
Shapiro-Wilk test. Analysis of categorical variables was carried out using either χ2 test or 
Fischer’s exact test. Statistical significance was set a p<0.05. 
 
Survival data were estimated using the Kaplan-Meier method and were compared using a 
stratified log-rank test. Univariate analysis was used to identify prognostic factors for OS. 
Prognostic factors with a p-value<0.05 were included in a cox regression model. A cox 
regression model of univariate factors of p<0.1 and p<0.2 was constructed to further 
investigate importance of prognostic factors. In multivariate analysis, significance was 
determined by p<0.05. All statistical analysis was carried out using SPSS (v.24.0.0.0, IBM, 
Armonk, NY, USA).  
 
3. Results 
A total of 80 consecutive patients were treated for breast cancer liver metastases (BCLM) at 
KCH between 2005 and 2016. KCH is a tertiary care centre and consequently follow-up for a 
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number of patients was carried out in their home institution. 19 patients were excluded from 
analysis (followed up at home institution, n=8; MDM outcome different to included 
treatments, n=11). The study cohort comprised of 61 patients; 23(38%) underwent 
hepatectomy, 11(18%) underwent RFA, and 27(44%) had chemotherapy only. The median 
follow-up for patients was 34 months(range: 1-91). 
 
The median age of the study population at primary diagnosis was 54yrs(range: 26-94). There 
was no significant difference between the ages of the treatment arms. Those who underwent 
hepatectomy (median 54yrs; range 26-77), RFA (53yrs; 46-60) and chemotherapy (54yrs; 40-
92; p=0.201) were of similar ages (Table 1). The primary cancer was typically intraductal 
carcinoma (hepatectomy 100%, RFA 89%; chemotherapy 88%; p=0.348). There were no 
significant differences in the prevalence of positive ER(p=0.127), PR(p=0.287) or HER2 
receptors(p=0.647). Those who underwent hepatectomy (13 months; range: 0-90 months) as 
treatment for their BCLM had a shorter disease free interval from breast cancer diagnosis to 
BCLM diagnosis than RFA (36 months; range: 0-168 months) or chemotherapy (55 months; 
range: 0-192 months; p=0.010).  
 
The clinical and pathological features of BCLM are summarised in Table 2. The number of 
liver metastases was fewer in the hepatectomy patients (1.6 ±1.0) compared to RFA (2.6 
±2.7) and chemotherapy (5.5 ± 2.9; p<0.001). Chemotherapy patients (n=17, 63%) had a 
significantly greater number of BCLM with bilobar distribution than RFA (n=4, 36%) or 
hepatectomy (n=4, 17%; p=0.002). Concomitant extrahepatic disease was most prevalent in 
chemotherapy patients (n=17, 63%; p=0.005). A higher proportion of patients who underwent 
hepatectomy (n=19, 95%) and RFA (n=7, 88%) as their definitive treatment had either a good 
or partial response to chemotherapy than for those who chemotherapy was the definitive 
treatment (n=6, 33%; p<0.001).  
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3.1 Outcomes 
The median DFS for hepatectomy, RFA and chemotherapy was 25, 28 and 0 months 
respectfully (p<0.001). Surgical resection patients had an improved median OS compared to 
chemotherapy (49 v 20 months; p<0.001). RFA showed comparable survival benefit (37 v 20 
months; p=0.011). Resection and RFA patients had no significant difference in overall 
survival (49 v 37; p=0.854). Survival analysis is displayed graphically via Kaplan-Meier 
curves (Figure 2). This identified that resection(p=0.002) and RFA(p=0.001) were associated 
with improved OS compared to chemotherapy. 1-, 3- and 5-year OS rates were 100%, 95% 
and 56% for the hepatectomy cohort, 100%, 100% 100% for the RFA cohort and 81%, 51% 
and 25% for the chemotherapy group. In comparison of hepatectomy and RFA subgroups 
neither groups suffered post-operative mortality. Postoperative morbidity was nil in the RFA 
group. There were 4 incidences(17%) of 90-day morbidity in the hepatectomy group (bile 
leak and narrowing of the common bile duct n=1; subdural haematoma n=1; seizure activity 
due to cerebral metastases n=1; not recorded n=1). 
 
3.2 Prognostic Factors 
Table 3 outlines the variables that were examined as possible predictive markers for OS.  The 
following factors were identified as being associated with reduced survival: extrahepatic 
metastases (HR=2.47; p=0.043), lack of response to chemotherapy (HR=6.06; p=0.003) and 
chemotherapeutic treatment compared to resection (HR=4.49; p=0.003). There was no 
statistically significant correlation between bone metastases and reduced survival (HR=2.37; 
p=0.051). R0 resection was found to be associated with improved survival (HR=0.18; 
p=0.038). Multivariate analysis found extrahepatic disease to be associated with a poorer 
prognosis (HR=14.21; 95% confidence interval 1.08-186.94; p=0.044) and R0 resection to be 
associated with improved prognosis (HR=0.068; 95% CI 0.01-0.69; p=0.023). It was not 
possible to perform a reliable multivariate analysis using factors with significance p<0.1 or 
p<0.2 at univariate analysis due to the presence of linearly dependent covariables. 
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4. Discussion 
It is currently unclear as to optimum treatment strategy for patients with BCLM due to an 
absence of randomised data comparing treatment modalities. The results of this study showed 
that hepatectomy and RFA were associated with 56% and 100% 5-year OS respectively. This 
compared to 25% overall survival in patients who received chemotherapy. In addition to this 
there were no peri-operative deaths following hepatectomy or RFA. Moreover, the incidence 
of morbidity following invasive treatment was 17% in hepatectomy patients and 0% in RFA 
patients. These results indicate that hepatectomy and RFA are safe to use and are associated 
with improved survival in comparison to medical treatment for BCLM. The most recent 
systematic review on resection and ablation in BCLM treatment demonstrated 5-year OS of 
21-61% and 24-41% respectively(14). The findings for our study compare favourably in 
comparison to these results.  
 
The improved 5-year OS data may be attributed to the implementation of the treatment 
algorithm. The algorithm aims to guide MDM decision making to utilise both surgical therapy 
alongside best medical therapy where safe to do so.  Cytoreductive surgery has been shown in 
other metastatic disease to improve OS in select patient cohorts, despite limitations with 
disease recurrence(23,24). Resection of cancer cells may provide an immunological benefit. 
Cancer cells have been demonstrated to reduce the patient immune response either by 
disabling the response directly or by recruitment or immunosuppressive factors(25). Evasion 
of the immune system has been identified as one of the emerging hallmarks of cancer(26). 
Clear surgical margins may therefore provide additional immunological benefit to improve 
OS. Moreover, chemotherapy kills cancer cells via log-kill hypothesis. Surgical resection or 
RFA with best medical therapy, especially in chemotherapy responsive cancers, increases the 
likelihood of effective cancer cell clearance(27). Moreover, surgical therapy helps to reduce 
the development of chemotherapy resistance. Resistance to medical therapy can occur 
through a number of mechanisms, one of which is associated with tumour size. Tumours can 
outstrip their blood supply, preventing adequate concentrations of chemotherapeutic agents 
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infiltrating the tumour(28). Surgery and RFA therefore can help prevent chemotherapy 
resistance and eventual treatment failure.  
 
These differences may also be explained by the comparison in timeframes between studies. 
The systematic review included patients treated from 1978-2008, whilst the patients in this 
observational series were treated between 2005 and 2016. There is a a trend towards 
improved overall survival in patients diagnosed with breast cancer more recently compared to 
their historical counterparts(4-6). Moreover, treatment was based at KCH, a tertiary liver 
disease centre. Studies have consecutively shown that increased specialisation and volume of 
procedures carried out by both individual surgeons and the centres themselves result in 
improved outcomes(29,30). This is integral in identifying the most appropriate treatment 
algorithms for individual centres and indeed regional workforce planning. 
 
Hepatectomy and RFA have only previously been compared to medical treatment in a 2016 
case-control study. This found no statistically significant differences between the 5-year OS 
of patients who underwent hepatectomy or RFA(38%) or had medical therapy(39%)(31). 
These differences may be as a result of the difference between responses to chemotherapy in 
the patients reported in this study. Both hepatectomy(94%) and RFA(86%) had a high 
proportion of patients who had disease regression as a result of chemotherapy, according to 
RECIST criteria(21). Univariate analysis found lack of response to chemotherapy to be a 
predictive factor for poor prognosis, which might have contributed to the poorer OS outcomes 
in the chemotherapy group. Combination therapy of chemotherapy and surgery will have 
allowed for complete clearance of BCLM and simultaneous treatment of micrometastases in 
those that were responsive. This highlights the potential for the use of medical therapy for 
downstaging BCLM. Utilising surgery in patients with tumours who are responsive to 
chemotherapy can also help to prevent significant sequelae associated with long-term 
chemotherapy treatment, especially in the liver(32). Medical therapy has previously been 
shown to improve survival in CLM by downstaging hepatic disease to allow resection(33,34). 
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However, no studies have examined this effect in BCLM treatment. Future studies analysing 
the survival benefits of resection following downstaging of BCLM will help in the production 
of management guidelines. In the downstaging of tumours it is also important to consider at 
which point it becomes appropriate to introduce locoregional treatments. In order to ensure 
that resection is conducted in a timely manner tumours should be reassessed frequently for 
response to medical therapy. It is recommended that if response is not achieved within 6 
months then the treatment strategy should be reassessed to optimise quality of life(35). 
Moreover, in analysis of the data presented in this study we note that 18% patients treated 
with RFA had more than 5 metastases. RFA in patients with greater than 5 metastases has 
previously been recommended against, however the recent CIRSE guidelines indicate that 
this should no longer be an absolute contraindication providing complete ablation of all 
lesions can be completed(36). Utilisation of this approach in theory will also allow for more 
patients to be treated with curative intent.  
 
The presence of extrahepatic metastases was found to be predictive of poor survival on 
multivariate analysis(HR=14.21). Two previous studies have also found extrahepatic disease 
to worsen prognosis in BCLM(37,38). The manifestation of coexisting extrahepatic disease is 
indicative of more aggressive disease and limits the ability for resection and RFA to provide 
clearance of metastatic deposits. In CLM, extrahepatic disease no longer precludes a patient 
from surgery so long as there is good response to chemotherapy and the disease is 
resectable(33). CLM however are as a result of haematogenous spread though the portal tract, 
whilst BCLM indicate further systemic spread and the presence of micro-metastases, possibly 
contraindication curative resection or RFA. On univariate analysis bone metastases were not 
found to reduce OS to statistically significant levels(HR=2.37), indicating that isolated bone 
metastases may not contraindicate surgical resection. Bone metastases in breast cancer may 
be the result of local invasion from the primary cancer. Prospective trials should be 
implemented to identify if ablation or resection in combination with adjuvant chemotherapy 
can be utilised to achieve complete metastatic clearance in this cohort. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
 
It is important to analyse these results in light of the methodological limitations. As a 
retrospective cohort study, these results are subject to selection bias. Moreover, some patients 
were not included in the present study due to being followed up at their home institution, 
compounding the selection bias. The sample size of this study was limited and the 
methodology would have been improved by including a higher number of patients. This study 
has however analysed RFA and resection as separate therapies. This reduced the sample sizes 
of the group, however, as genuine clinical equipoise exists between the effectiveness of these 
treatments in BCLM it is beneficial to examine the differences between these cohorts. 
Moreover, the patients included in this study were treated over a short time period. Whilst 
increasing the time period would have increased the sample size it may have biased the 
results due to continuing development of improved therapies to treat breast cancer(4-6). 
Additionally, these patients were all treated after 2005, indicating that the treatments used are 
in line with current beliefs on best practice.  Finally, in regards to treatment subgroups, it is 
important to be aware of the differences in clinicopathological characteristics of each patient 
cohort and that cox regression analysis cannot completely exclude this bias. As highlighted by 
the recent consensus on the treatment of advanced breast cancer, randomised controlled trials 
are urgently needed to guide best practice according to these characteristics(13).   
 
4.1 Conclusions 
Resection of BCLM appears to improve OS in selected patients with BCLM compared to 
medical therapy alone. However, no differences were distinguished in OS between RFA and 
resection cohorts. Extrahepatic disease was found to be associated with reduced OS. This 
indicates that BCLM patients are most likely to benefit from resection or RFA in the absence 
of macroscopic extrahepatic disease. Nevertheless, randomised controlled trials are required 
in the future to elicit which patients would most benefit from liver directed therapies.   
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Tables 
Table 1 – Clinicopathological characteristics of primary breast cancer 
Treatment 
Hepatectomy 
(n=23) 
RFA         
(n=11) 
Chemotherapy 
(n=27) P-value 
Age at diagnosis of primary breast cancer 54 (26-77) 53 (36-60) 54 (40-94) 0.201 
Follow up period from BCLM to last follow 
up, months 48 (4-77) 43 (17-91) 16 (1-48) - 
Time interval from breast cancer diagnosis 
to BCLM diagnosis, months 13 (0-90) 36 (0-168) 55 (0-192) 0.010 
American Joint Committee on Cancer 
(AJCC) staging (7th edition)       0.179 
0 0 1 (25%) 3 (30%)   
I 1 (10%) 0 3 (30%)   
II 3 (30%) 2 (50%) 2 (20%)   
III 2 (20%) 1 (25%) 2 (20%)   
IV 4 (40%) 0 0   
Tumour grade       0.406 
I 0 0 0   
II 8 (53%) 2 (33%) 11 (65%)   
III 7 (47%) 4 (67%) 6 (35%)   
Histological subtype       0.348 
Intraductal carcinoma 17 (100%) 8 (89%) 15 (88%)   
Intralobular carcinoma 0 1 (11%) 2 (12%)   
Receptor status         
Estrogen Receptor (ER) positive 17 (94%) 5 (63%) 12 (80%) 0.127 
Progesterone Receptor (PR) positive 9 (50%) 2 (25%) 4 (27%) 0.287 
Human Epidermal Growth Factor 
Receptor 2 (HER2) positive 5 (28%) 1 (14%) 5 (33%) 0.647 
Neoadjuvant chemotherapy before breast 
surgery 9 (43%) 4 (44%) 6 (29%) 0.560 
Adjuvant chemotherapy after breast 
surgery 11 (48%) 5 (50%) 14 (61%) 0.654 
Adjuvant hormone therapy after breast 
surgery 16 (73%) 5 (50%) 17 (74%) 0.351 
Adjuvant herceptin treatment after breast 
surgery 6 (27%) 1 (10%) 4 (17%) 0.484 
Type of breast surgery 0.747 
Breast conserving surgery 4 (20%) 3 (30%) 7 (29%)   
Mastectomy 16 (80%) 7 (70%) 17 (71%)   
 
BCLM – Breast Cancer Liver Metastases 
RFA – Radiofrequency Ablation 
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Table 2 – Clinicopathological features of BCLM and survival 
Treatment 
Hepatectomy 
(n=23) 
RFA         
(n=11) 
Chemotherapy 
(n=27) P-value 
Synchronous presentation 8 (35%) 3 (27%) 4 (15%) 0.256 
Number of liver metastases 1.6 ± 1.0 2.6 ± 2.7 5.5 ± 2.9 <0.001 
Number of liver metastases >5 0 2 (18%) 17 (65%) <0.001 
Solitary liver metastases 15 (65%) 5 (45%) 3 (11%) <0.001 
Bilobar distribution 4 (17%) 4 (36%) 17 (63%) 0.002 
Largest liver metastasis, mm 46.7 ± 31.2 10.8 ± 1.1 23.7 ± 56.2 0.045 
Largest tumour size >50mm 1 (14%) 0 1 (10%) 0.842 
Receptor status         
Estrogen Receptor (ER) positive 6 (46%) 0 1 (100%) 0.364 
Progesterone Receptor (PR) positive 5 (38%) 0 0 0.562 
Human Epidermal Growth Factor 
Receptor 2 (HER2) positive 
3 (21%) 0 0 0.768 
Response to chemotherapy 19 (95%) 7 (88%) 6 (33%) <0.001 
Extra-hepatic disease         
Any 4 (17%) 4 (36%) 17 (63%) 0.005 
Bone 4 (17%) 3 (27%) 14 (52%) 0.068 
Lung 0 3 (27%) 7 (26%) 0.027 
Major resection 14 (64%) 0 - 0.037 
R0 resection 16 (73%) 2 (100%) - 0.394 
90-day mortality 0 0 - - 
90-day morbidity 4 (17%) 0 - 0.432 
Hospital stay, days 9.5 ± 7.9 5.3 ± 3.8 - 0.639 
Disease free survival (DFS), months 25 (0-72) 28 (15-91) 0 (0-33) <0.001 
Overall survival (OS)         
Median OS, months 49 (4-77) 37 (17-91) 20 (1-48) <0.001 
1-year OS 100% 100% 81%   
3-year OS 95% 100% 51%   
5-year OS 56% 100% 25%   
 
RFA – Radiofrequency Ablation 
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Table 3 – Univariate analyses 
Variable n HR (95% CI) P-value 
Disease Free Interval       
≤36 months 36 1   
>36 months 24 1.32 (0.54-3.26) 0.547 
Synchronicity       
Metachronous 45 1   
Synchronous 15 1.37 (0.49-3.81) 0.547 
Tumour Number       
Single  24 1   
Multiple 37 1.97 (0.75-5.13) 0.166 
Distribution       
Unilobar 31 1   
Bilobar 29 2.09 (0.85-5.16) 0.110 
Tumour Size       
≤30mm 10 1   
>30mm 9 0.67 (0.13-3.49) 0.636 
Response to Chemotherapy   
Response 32 1   
Stable/Regression 14 6.06 (1.87-19.64) 0.003 
Extrahepatic Disease       
Absent 36 1   
Present 25 2.47 (1.03-5.94) 0.043 
Bone Metastases   
Absent 40 1   
Present 21 2.37 (0.99-5.63) 0.051 
Resection       
Minor 11 1   
Major 14 4.38 (0.51-37.59) 0.178 
Resection Margin   
R1/R2 5 1   
R0  18 0.18 (0.04-0.91) 0.038 
ER Receptor Status       
Positive 7 1   
Negative 8 7.77 (0.78-77.24) 0.080 
PR Receptor Status   
Positive 5 1   
Negative 10 2.78 (0.39-20.07) 0.310 
HER2 Receptor Status       
Positive 3 1   
Negative 13 0.79 (0.08-7.80) 0.839 
Treatment   
Hepatectomy 23 1   
RFA 11 0.18 (0.00-1.55) 0.077 
Chemotherapy 27 4.49 (1.66-12.09) 0.003 
HR – Hazard Ratio; RFA – Radiofrequency Ablation 
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HPB MDM – Hepatopancreatobiliary multidisciplinary board meeting 
EHD – Extrahepatic disease 
BMT – Best Medical Treatment 
RFA – Radiofrequency Ablation 
SIRT – Selective internal radiation therapy 
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Months 6 12 18 24 30 36 42 48 54 60 
Chemotherapy 22 20 14 10 9 6 4 1 1 1 
Hepatectomy 22 22 22 19 18 17 13 12 10 5 
 
 
1 – Chemotherapy, 2 – Hepatectomy, p=0.002 
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Months 6 12 18 24 30 36 42 48 54 60 
Hepatectomy 22 22 22 19 18 17 13 12 10 5 
RFA 11 11 9 8 6 6 5 4 4 4 
 
2 – Hepatectomy, 3- Radiofrequency Ablation, p=0.110 
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Months 6 12 18 24 30 36 42 48 54 60 
Chemotherapy 22 20 14 10 9 6 4 1 1 1 
RFA 11 11 9 8 6 6 5 4 4 4 
 
 
1 – Chemotherapy, 3 – Radiofrequency Ablation, p=0.001 
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Highlights 
 
• Patients who underwent locoregional treatment for BCLM had improved overall 
survival. 
• Extrahepatic disease and R0 resection were identified as prognostic factors for overall 
survival 
• Presence of bony metastases was not a prognostic factor of overall survival. 
 
